EIF2AK2 and neoplasm: Since the association of p53 tumor alterations with patient prognosis and response to adjuvant chemotherapy has been widely studied, with contradictory findings [62], [63], [64], the analysis of additional prognostic and preventive molecular markers such as PKR could be of clinical interest.